SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is surging as market participants react to headlines regarding potential diplomatic negotiations to end the ongoing conflict in the Middle East, despite ongoing volatility in oil prices. The community remains deeply divided, with many debating whether the rally is a genuine recovery or a temporary relief pop driven by unverified news and algorithmic positioning.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The market is experiencing a high-volatility relief rally driven by conflicting headlines regarding potential war de-escalation in the Middle East and end-of-quarter portfolio rebalancing. While many traders are skeptical and labeling the move a bull trap, the community remains deeply divided, with bears pointing to elevated oil prices as a sign of underlying fragility while bulls are aggressively buying the dip on expectations of institutional support.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trading higher as the market weighs escalating conflict in the Middle East and the uncertainty surrounding the Strait of Hormuz against mixed signals from U.S. leadership regarding peace negotiations. The community is sharply divided, with many traders betting on further supply shocks and potential price surges, while others view current levels as an overextended rally susceptible to sudden corrections.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as investors debate whether the current price represents a deep-value buying opportunity or a signal of further downside, with the community closely tracking high short interest, institutional accumulation, and technical support levels. Despite frustration over consistent downward pressure and the recent executive transition, many long-term bulls remain focused on the company's patent portfolio, expanding enterprise partnerships, and projected growth in agentic AI.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors gear up for the upcoming AAD conference in Denver, where clinical data regarding its lead skin disease drug will be presented. The community is actively discussing the drug's potential for best-in-class status in treating hidradenitis suppurativa, fueling speculation around clinical breakthroughs, M&A possibilities, and potential price movement.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is experiencing heightened volatility and downward pressure as market sentiment reacts to the ongoing conflict in the Middle East and concerns over energy inflation. Community discussions are centered on the impact of shifting geopolitical news, Iranian energy infrastructure threats, and the potential for a broader economic recession, with many traders debating whether the market is reaching a capitulation point or if further declines are inevitable.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector is experiencing significant volatility and renewed investor interest, driven by a wave of high-premium M&A activity and positive data readouts for late-stage pipeline assets. While broader market uncertainty and geopolitical concerns have created a tug-of-war in price action, the community remains intensely focused on identifying potential buyout targets and monitoring institutional accumulation patterns within small-cap biotech leaders.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is facing intense volatility as market participants debate the company's aggressive dilution strategy for Bitcoin accumulation amidst broader macroeconomic concerns and recent quantum computing headlines. The community remains deeply polarized, with bulls highlighting the potential of Saylor's treasury model while bears increasingly warn of sustainability risks, dividend pressures, and potential downside price targets.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming release of the company's 2025 Annual Report and earnings call, which are being closely watched for signs of a turnaround. The community is actively debating the stock's potential for a squeeze, citing high short interest and a significant valuation gap compared to its underlying assets, while tracking the company's recent debt reduction efforts.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around its long-standing presence in the market and maintains a high-energy, humorous social media campaign. Investors are actively discussing the token's mass-adoption goals while utilizing the project's decentralized swap options to grow their holdings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BCTX  Lots of big money poling out of big name stocks and sitting on the sidelines because of the war in the middle East . ￼A positive phase 3 could be bigger than all of us bulls are thinking with lots of cash on sidelines right now.

Uschi Long

henry bennett

Phillip Longacre

StockTwits for iOS

BriaCell Therapeutics Corp

  Lots of big money poling out of big name stocks and sitting on the sidelines because of the war in the middle East . ￼A positive phase 3 could be bigger than all of us bulls are thinking with lots of cash on sidelines right now.

Banco de Chile

Bitcoin Cash

Justin

@JediGreen I remain cautiously optimistic, at this point. I think they will almost certainly gain FDA approval in the current setting, and may become the new SOC for the patient population. However, I also have become convinced that BP doesn&#39;t really care about late-stage, metastatic, terminal patients. They all want that 1st line golden ticket. 
Ultimately, even if IMT is approved, we must see how much can be translated to oter cell lines, like prostate and melanoma. While the specific research lines were chosen due to genetic similarities to SV-BR-1-GM, many aspects of the cell line (like post-translational modifications) aren&#39;t genetically coded, but driven by cancer mutations. 
They still must prove (in humans) that the tech can expand into a platform for multiple settings, before they can command multiple billions for their IP. They also need to investigate as an earlier line of therapy. Hopefully, they can revive the investigator-initiated studies along those lines.

Tyler

AceInHole

StockTwits Web

 I remain cautiously optimistic, at this point. I think they will almost certainly gain FDA approval in the current setting, and may become the new SOC for the patient population. However, I also have become convinced that BP doesn't really care about late-stage, metastatic, terminal patients. They all want that 1st line golden ticket. 
Ultimately, even if IMT is approved, we must see how much can be translated to oter cell lines, like prostate and melanoma. While the specific research lines were chosen due to genetic similarities to SV-BR-1-GM, many aspects of the cell line (like post-translational modifications) aren't genetically coded, but driven by cancer mutations. 
They still must prove (in humans) that the tech can expand into a platform for multiple settings, before they can command multiple billions for their IP. They also need to investigate as an earlier line of therapy. Hopefully, they can revive the investigator-initiated studies along those lines.

CERo Therapeutics Holdings Inc

Jeff Thompson

@Fvalstounge  I’m not talking about big Pharma  money. I’m talking about lots of rich people selling stock out of big companies from all sectors of the market right now  sitting on sidelines  with piles of cash because of global events right now. A positive phase 3 pr coming across computer screens with probably way more then average money sitting on the sidelines could be a chain reaction if people start chasing it.  ￼

  I’m not talking about big Pharma  money. I’m talking about lots of rich people selling stock out of big companies from all sectors of the market right now  sitting on sidelines  with piles of cash because of global events right now. A positive phase 3 pr coming across computer screens with probably way more then average money sitting on the sidelines could be a chain reaction if people start chasing it.  ￼